BRPI0910833A2 - Derivado de arilpirazinona como estimuladores da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para o tratamento de diabetes - Google Patents

Derivado de arilpirazinona como estimuladores da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para o tratamento de diabetes

Info

Publication number
BRPI0910833A2
BRPI0910833A2 BRPI0910833-5A BRPI0910833A BRPI0910833A2 BR PI0910833 A2 BRPI0910833 A2 BR PI0910833A2 BR PI0910833 A BRPI0910833 A BR PI0910833A BR PI0910833 A2 BRPI0910833 A2 BR PI0910833A2
Authority
BR
Brazil
Prior art keywords
arylpyrazinone
derivative
obtaining
methods
insulin secretion
Prior art date
Application number
BRPI0910833-5A
Other languages
English (en)
Inventor
Gerard Botton
Eric Valeur
Christine Charon
Mocheline Kergoat
Samer Elbawab
Original Assignee
Merck Patent Ges Mit Beschränkter Hatfung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschränkter Hatfung filed Critical Merck Patent Ges Mit Beschränkter Hatfung
Publication of BRPI0910833A2 publication Critical patent/BRPI0910833A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0910833-5A 2008-04-29 2009-03-31 Derivado de arilpirazinona como estimuladores da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para o tratamento de diabetes BRPI0910833A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08008165 2008-04-29
PCT/EP2009/002328 WO2009132739A1 (en) 2008-04-29 2009-03-31 Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (1)

Publication Number Publication Date
BRPI0910833A2 true BRPI0910833A2 (pt) 2015-08-11

Family

ID=40589704

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910833-5A BRPI0910833A2 (pt) 2008-04-29 2009-03-31 Derivado de arilpirazinona como estimuladores da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para o tratamento de diabetes

Country Status (25)

Country Link
US (2) US8815859B2 (pt)
EP (1) EP2268624B1 (pt)
JP (1) JP5498482B2 (pt)
KR (1) KR101687419B1 (pt)
CN (1) CN102015661B (pt)
AR (1) AR071518A1 (pt)
AU (1) AU2009242720B2 (pt)
BR (1) BRPI0910833A2 (pt)
CA (1) CA2722813C (pt)
CO (1) CO6310997A2 (pt)
CY (1) CY1114531T1 (pt)
DK (1) DK2268624T3 (pt)
EA (1) EA022345B1 (pt)
EC (1) ECSP10010642A (pt)
ES (1) ES2433210T3 (pt)
HR (1) HRP20130992T1 (pt)
IL (1) IL208959A (pt)
MX (1) MX2010011792A (pt)
NZ (1) NZ589555A (pt)
PL (1) PL2268624T3 (pt)
PT (1) PT2268624E (pt)
SI (1) SI2268624T1 (pt)
UA (1) UA103191C2 (pt)
WO (1) WO2009132739A1 (pt)
ZA (1) ZA201008505B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736472A1 (en) * 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013066838A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62198671A (ja) 1986-02-25 1987-09-02 Toyo Jozo Co Ltd 1−置換アルキル1,2−ジヒドロ−2−ピラジノン誘導体
CA2446980A1 (en) * 2001-05-14 2002-11-21 Argyrios G. Arvanitis Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
NZ537629A (en) 2002-07-19 2007-05-31 Biovitrum Ab Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders
FR2857867B1 (fr) * 2003-07-25 2005-10-14 Oreal Utilisation en coloration capillaire de derives de ninhydrine portant un groupe heteroalkyle
EP1732564A1 (en) 2004-03-29 2006-12-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
NZ555419A (en) * 2004-11-03 2009-07-31 Curis Inc Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto
TW200640881A (en) * 2005-02-15 2006-12-01 Du Pont Fungicidal pyrazine derivatives
ES2412007T3 (es) 2005-12-21 2013-07-09 Janssen Pharmaceutica, N.V. Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1
AU2007261461A1 (en) 2006-06-21 2007-12-27 E. I. Du Pont De Nemours And Company Pyrazinones as cellular proliferation inhibitors

Also Published As

Publication number Publication date
CA2722813C (en) 2017-03-21
WO2009132739A1 (en) 2009-11-05
IL208959A (en) 2015-09-24
EP2268624A1 (en) 2011-01-05
JP5498482B2 (ja) 2014-05-21
EA022345B1 (ru) 2015-12-30
US20110046159A1 (en) 2011-02-24
PL2268624T3 (pl) 2014-01-31
JP2011518847A (ja) 2011-06-30
CN102015661B (zh) 2014-05-14
ECSP10010642A (es) 2010-12-30
HRP20130992T1 (hr) 2013-11-22
CY1114531T1 (el) 2016-10-05
EP2268624B1 (en) 2013-07-31
ES2433210T3 (es) 2013-12-09
EA201001688A1 (ru) 2011-06-30
NZ589555A (en) 2012-08-31
ZA201008505B (en) 2012-01-25
MX2010011792A (es) 2010-11-25
KR101687419B1 (ko) 2016-12-19
SI2268624T1 (sl) 2013-12-31
DK2268624T3 (da) 2013-11-04
CO6310997A2 (es) 2011-08-22
CA2722813A1 (en) 2009-11-05
AU2009242720B2 (en) 2014-03-27
US8815859B2 (en) 2014-08-26
US20140329837A1 (en) 2014-11-06
AU2009242720A1 (en) 2009-11-05
IL208959A0 (en) 2011-01-31
UA103191C2 (ru) 2013-09-25
US9233937B2 (en) 2016-01-12
CN102015661A (zh) 2011-04-13
KR20100135313A (ko) 2010-12-24
AR071518A1 (es) 2010-06-23
PT2268624E (pt) 2013-11-07

Similar Documents

Publication Publication Date Title
BRPI0908406A2 (pt) Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetes
BRPI1012642A2 (pt) formulação de insulina e método para o tratamento de um indivíduo diabético.
BRPI0921389A2 (pt) seringa de um só uso, de inutilização automática
DK2328636T3 (da) Anordning til forbedret subkutan insulinabsorption
BRPI0911782A2 (pt) composição de insulina de ação super rápida
BRPI0907110A2 (pt) dispositivo de injeção para realizar injeções médicas
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
BRPI0822380A2 (pt) agulha para coleta de sangue com retrocesso
BRPI0908456A2 (pt) derivados de bifenil restritos estruturalmente para uso como inibidores do vírus da hepatite c
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
DK2555807T3 (da) Skabelon-øceller og små øcelleklynger til behandling af diabetes
BRPI0817198A2 (pt) (ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
BRPI0911594A2 (pt) di-hidropirazolonas substistuídas, seu processo de preparação e seu uso, bem como medicamentos
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
CL2011002041A1 (es) Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
BRPI0911545A2 (pt) dispositvo para a produção de um componente assim como método e componente
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina
BRPI0908544A2 (pt) derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes
BRPI1006996A2 (pt) composição, método e uso
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
BRPI0821827A2 (pt) Derivados de beta-aminoácidos para tratamento de diabetes
BRPI0908569A2 (pt) estimuladores de secreção de insulina derivados de piridopirazinonas, métodos para obtê-los e uso dos mesmos para o tratamento de diabetes
BRPI0914900A2 (pt) compostos de amida, métodos de preparação e usos dos mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.